Opus Genetics Inc. (OCUP) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Opus Genetics Inc. (OCUP:NASDAQ), powered by AI.

Current Price
$4.55
P/E Ratio
-9.8
Market Cap
98M
Sector
Healthcare
What is the Opus Genetics Inc. stock price forecast?

Opus Genetics Inc. is currently trading at $4.55. View real-time AI analysis on Alpha Lenz.

What is Opus Genetics Inc. insider trading activity?

View the latest insider trading data for Opus Genetics Inc. on Alpha Lenz.

What is Opus Genetics Inc.'s P/E ratio?

Opus Genetics Inc.'s P/E ratio is -9.8.

Opus Genetics Inc.

$4.55
NASDAQOCUP
Ask about Opus Genetics Inc.'s future dividend policy...
Alpha Chat Insight

Opus Genetics Inc. trades at a P/E of -9.8 (undervalued) with modest ROE of -20.8%.

Ask for details

Company Overview

Opus Genetics Inc. is a biotechnology company focusing on developing innovative gene therapies for inherited retinal diseases. Their primary mission is to address unmet medical needs for patients suffering from these rare genetic conditions that often lead to severe visual impairment or blindness. Opus Genetics leverages advanced gene therapy techniques to design and deliver solutions that target the root causes of such vision disorders. By concentrating on the sensory system, particularly the eyes, they aim to restore vision or significantly stall disease progression. The company operates at the intersections of genetic research, clinical development, and ophthalmology, influencing the broader healthcare and medical research sectors. As part of a niche but crucial industry within biotechnology, Opus Genetics plays a significant role in pioneering treatments that could potentially transform the lives of those affected by genetic ocular diseases. Their work underscores the vital importance of breakthrough biomedical research and innovation in improving quality of life for patients with chronic and debilitating conditions.

CEOMr. George Magrath M.B.A., M.D., M.S.
SectorHealthcare
IndustryBiotechnology
Employees18

Company Statistics

(FY 2023)

Profile

Market Cap$98.23M
Revenue$19.05M
Shares Out0.00
Employees18

Margins

GrossN/A
EBITDA-52.75%
Operating-55.45%
Pre-Tax-52.36%
Net-52.42%

Valuation

P/E-9.84
P/B1.97
EV/Sales5.16
EV/EBITDA-4.75
P/FCF-88.34

Growth (CAGR)

Rev 3YrN/A
Rev 5YrN/A
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-19.40%
ROE-20.77%
ROIC-19.38%

Financial Health

Cash & Cash Equivalents$50.50M
Net Debt$-46.46M
Debt/Equity8.10%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Opus Genetics Inc. (Healthcare) Stock Forecast & Analysis $4.55 | Alpha Lenz